{
    "symbol": "URGN",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-10 12:05:30",
    "content": " These may include statements regarding our ongoing commercialization activities relating to Jelmyto, the expected benefits of the FDA's expansion of the end-use period for Jelmyto, our ongoing and planned clinical trials, commercial and clinical milestones in the year ahead, the growth potential for Jelmyto, the design potential benefits and commercial potential for UGN-102, if approved, the design, potential benefits and commercial potential of UGN-301, potential future commercialization activities for UGN-102 if approved, data presentations, expected regulatory filings and timing thereof, future research and development efforts and our financial and other corporate goals, among other things. UroGen reported a net product revenue of Jelmyto for the third quarter of 2022 of $16.1 million, compared to $11.4 million in the third quarter of 2021, representing a 41% increase from the same period last year. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open."
}